Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.

Abstract:

:We retrospectively evaluated the role of rituximab (R) in maintenance treatment after autologous stem cell transplantation performed in patients with relapsed follicular lymphoma. We compared the outcome of 67 follicular lymphoma (FL) patients according to the use of rituximab maintenance (RM) or not. All patients received rituximab plus chemotherapy before autologous stem-cell transplantation (ASCT). Patients received median of two lines of prior therapy. The RM schedule was one injection of rituximab every 3 months for 2 years. Median follow-up is 4.6 years. The 3-year progression-free survival (PFS) after ASCT was 86 % with RM vs. 46 % without (p = 0.0045). Median is not reached in the RM arm vs. 31 months in non-RM arm. The 3-year OS was 96 % with RM vs. 78 % without (p = 0.059). The present monocentric study shows that 2 years of RM after ASCT significantly increases response duration for non-naive rituximab relapsed FL patients compared with observation.

journal_name

Ann Hematol

journal_title

Annals of hematology

authors

Bourcier J,Gastinne T,Leux C,Moreau A,Bossard C,Mahé B,Blin N,Dubruille V,Touzeau C,Voldoire M,Guillaume T,Peterlin P,Gallas P,Garnier A,Maisonneuve H,Moreau P,Juge-Morineau N,Jardel H,Chevallier P,Moreau P,Le Gou

doi

10.1007/s00277-016-2705-z

subject

Has Abstract

pub_date

2016-08-01 00:00:00

pages

1287-93

issue

8

eissn

0939-5555

issn

1432-0584

pii

10.1007/s00277-016-2705-z

journal_volume

95

pub_type

杂志文章
  • Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.

    abstract::There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessm...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-019-03705-y

    authors: Caocci G,Mulas O,Abruzzese E,Iurlo A,Annunziata M,Orlandi EM,Galimberti S,Binotto G,Sgherza N,Luciano L,Martino B,Russo Rossi A,Bonifacio M,Fozza C,Trawinska MM,Cattaneo D,Elena C,Baratè C,De Gregorio F,Molica M,L

    更新日期:2019-08-01 00:00:00

  • Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis.

    abstract::The Wilms' tumor 1 (WT1) expression has been recognized in a substantial number of acute myeloid leukemia (AML) patients. Some studies indicated the association of diagnosed WT1 higher expression (WT1(H)) and poor outcome in the AML patients, while other studies had different opinions. Therefore, we performed a meta-a...

    journal_title:Annals of hematology

    pub_type: 杂志文章,meta分析

    doi:10.1007/s00277-014-2295-6

    authors: Yi-Ning Y,Xiao-rui W,Chu-xian Z,Chun W,You-wen Q

    更新日期:2015-06-01 00:00:00

  • The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study.

    abstract::Venous thromboembolism (VTE) is a well-recognized complication in pediatric oncology patients. Studies in adult oncology patients have suggested a potential negative association between VTE and survival, but this association has not been examined in pediatric patients yet. The aim of this study was to assess the assoc...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-018-3371-0

    authors: Forbrigger Z,Kuhle S,Brown MM,Moorehead PC,Digout C,Kulkarni K

    更新日期:2018-10-01 00:00:00

  • Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.

    abstract::Although retreatment with alemtuzumab in relapsing B-cell chronic lymphocytic leukemia (CLL) may be beneficial, there has thus far been no thorough analysis available on this topic. Data were collected from 30 chemotherapy-pretreated patients with progressive CLL who had received alemtuzumab twice in consecutive, dist...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-011-1192-5

    authors: Fiegl M,Falkner F,Steurer M,Zojer N,Hopfinger G,Haslbauer F,Winder G,Voskova D,Andel J,Lang A,Brychtova Y,Mayer J,Greil R,Gastl G,Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.,Czech Leuk

    更新日期:2011-09-01 00:00:00

  • PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.

    abstract::Symptomatic multiple myeloma (MM) is a plasma cell neoplasm that represents the final stage of a continuum of clinical conditions that start from monoclonal gammopathy of unknown significance (MGUS), then transits in the more advance, but still asymptomatic, smoldering MM (SMM), with a final evolution in symptomatic M...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-019-03648-4

    authors: Mussetti A,Pellegrinelli A,Cieri N,Garzone G,Dominoni F,Cabras A,Montefusco V

    更新日期:2019-07-01 00:00:00

  • Clinical applications of new antithrombotic agents.

    abstract::The clinical targets for which new generations of antithrombotics have been or are currently under clinical development are those associated with a high risk for thromboembolism, (a) patients undergoing general, orthopedic, major abdominal, and cancer surgery, to prevent venous thromboembolism; (b) patients with deep-...

    journal_title:Annals of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s002770050158

    authors: Beijering RJ,ten Cate H,ten Cate JW

    更新日期:1996-04-01 00:00:00

  • Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis.

    abstract::Patients previously diagnosed with invasive aspergillosis (IA) have been considered to be at risk for relapse of mycosis during subsequent hematopoietic transplant. Even with prophylactic measures, reactivation of the infection occurs in 29% of patients undergoing bone marrow transplantation (BMT). A period of neutrop...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770100311

    authors: Sevilla J,Hernandez-Maraver D,Aguado MJ,Ojeda E,Morado M,Hernandez-Navarro F

    更新日期:2001-08-01 00:00:00

  • Epstein-Barr virus infection in allogeneic marrow grafting: lessons for transplant physicians and virologists.

    abstract::The relationship between Epstein-Barr virus (EBV) and the host is profoundly disturbed by allogeneic bone marrow transplantation (BMT) because EBV resides in the recipient's hematopoietic system, which has to be destroyed in the majority of cases, and in the donor's hematopoietic system, i.e., the marrow graft. We hav...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/BF01715373

    authors: Gratama JW,Oosterveer MA,Lepoutre J,Fibbe WE,Ringdén O,Vossen JM,Willemze R,Bolhuis RL,van Rood JJ,Ernberg I

    更新日期:1992-06-01 00:00:00

  • Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.

    abstract::Treatment of relapse and primary progression in aggressive lymphoma remains unsatisfactory; outcome is still poor. Better treatment strategies are much needed for this patient population. The R1 study is a prospective multi-center phase I/II study evaluating a dose finding approach with a triple transplant regimen in ...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-016-2671-5

    authors: Hohloch K,Zeynalova S,Chapuy B,Pfreundschuh M,Loeffler M,Ziepert M,Feller AC,Trümper L,Hasenclever D,Wulf G,Schmitz N

    更新日期:2016-06-01 00:00:00

  • Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome.

    abstract::In some instances, because of the lack of mass formation and the absence of prominent lymph node enlargement, diagnosis of lymphoma-associated hemophagocytic syndrome (LAHS) is difficult, which results in the development of progressive disease with unfavorable prognosis. Therefore, in the diagnosis of secondary hemoph...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1239-7

    authors: Tabata C,Tabata R

    更新日期:2012-01-01 00:00:00

  • Treatment of primary defective iron-reutilization syndrome: revisited.

    abstract::We encountered two patients who presented with hypochromic-microcytic anemia and were refractory to iron therapy. The symptoms were suggestive of anemia of chronic disease (ACD); however, there was no evidence of any such disease, either inflammatory or malignant. These patients were reminiscent of patients originally...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770000180

    authors: Besa EC,Kim PW,Haurani FI

    更新日期:2000-08-01 00:00:00

  • Life-threatening cryoglobulinemia in HCV-negative Southern Chinese and a novel association with structural aortic abnormalities.

    abstract::Cryoglobulinemia is uncommon in Southern Chinese in Hong Kong, with tropical climates and low incidence of hepatitis C virus (HCV) infection. Eight positive cases were detected among 481 patients screened for cryoglobulins over a 10-year period. Three HCV carriers (38%) ran benign courses. The others included two carr...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-004-0955-7

    authors: Au WY,Kwok JS,Chu KM,Ma ES

    更新日期:2005-02-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases.

    abstract::Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for relapsed, advanced, and otherwise incurable non-Hodgkin's lymphomas (NHL) suggested by the existence of a graft-versus-lymphoma effect. The main complications are graft-versus-host disease and infections. We performed a retrospec...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-017-2934-9

    authors: Picleanu AM,Novelli S,Monter A,Garcia-Cadenas I,Caballero AC,Martino R,Esquirol A,Briones J,Sierra J

    更新日期:2017-05-01 00:00:00

  • In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.

    abstract::In vivo, growth factors are currently investigated for their capacity to trigger leukemic stem cells into cycle and thus overcome kinetic drug resistance. In this study, the susceptibility of leukemic clonogenic cells to individual growth factors was related to cytosine-arabinoside (Ara-C) sensitivity. The effects of ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/BF01737421

    authors: Van der Lely N,De Witte T,Wessels J,Raymakers R,Muus P,Preijers F

    更新日期:1994-05-01 00:00:00

  • Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.

    abstract::Established risk factors for thrombosis in essential thrombocythemia (ET) include age (≥ 60 years) and previous vascular events. Recently, also leukocytosis has been proposed in risk stratification of ET patients. We report a retrospective study on 532 ET patients followed for a median of 7.6 years. Sixty-four patient...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-010-1154-3

    authors: Palandri F,Polverelli N,Catani L,Ottaviani E,Baccarani M,Vianelli N

    更新日期:2011-08-01 00:00:00

  • Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2-chlorodeoxyadenosine.

    abstract::Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is an atypical lympho-proliferative disorder with borderline features that often constitute a diagnostic challenge for the hematopathologist and a therapeutic dilemma for the treating clinician. Morphologically, the involved lymph nodes in this disorder are...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050244

    authors: Sallah AS,Bernard S

    更新日期:1996-12-01 00:00:00

  • A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma.

    abstract::The requirement of antifungal prophylaxis has not been established in the chemotherapies for malignant lymphoma. This study was conducted to explore the incidence of invasive fungal diseases (IFD) and their risk factors in patients receiving salvage therapies for malignant lymphoma. We retrospectively analyzed 177 con...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-014-2093-1

    authors: Takaoka K,Nannya Y,Shinohara A,Arai S,Nakamura F,Kurokawa M

    更新日期:2014-10-01 00:00:00

  • Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice.

    abstract::Mesenchymal stem cells (MSCs) have emerged as a therapeutic approach in a range of medical fields, including regenerative medicine, cancer, autoimmune diseases, and inflammatory diseases, because of their unique properties of tissue repair and major histocompatibility complex-unmatched immunosuppression. Because both ...

    journal_title:Annals of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s00277-013-1796-z

    authors: Kim N,Im KI,Lim JY,Jeon EJ,Nam YS,Kim EJ,Cho SG

    更新日期:2013-10-01 00:00:00

  • The time-dependent autophagy protects against apoptosis with possible involvement of Sirt1 protein in multiple myeloma under nutrient depletion.

    abstract::The absence of researches about autophagy in multiple myeloma promoted us to explore the biological characteristics and role of autophagy induced by nutrient depletion in multiple myeloma (MM) cell line RPMI8226 cells. Both autophagic and apoptotic morphology were observed by TUNEL, transmission electron microscopy (T...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1315-z

    authors: Zeng R,He J,Peng J,Chen Y,Yi S,Zhao F,Cui G

    更新日期:2012-03-01 00:00:00

  • Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.

    abstract::It has been suggested that Asian and Western myelodysplastic syndrome (MDS) patients have different cytogenetic and prognostic features. In this study, we retrospectively analyzed clinical and cytogenetic data from 435 Chinese adult primary MDS patients. In addition, we evaluated the prognostic value of the World Heal...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-009-0861-0

    authors: Wang H,Wang X,Xu X,Lin G

    更新日期:2010-06-01 00:00:00

  • Allogeneic stem cell transplantation from related and unrelated donors for aplastic anaemia in adults--a single-centre experience.

    abstract::Aplastic anaemia (AA) is a rare bone marrow failure syndrome treated either by immunosuppressive therapy or allogeneic stem cell transplantation (SCT). At present, no randomised clinical trials evaluating both treatment options, and in particular SCT from unrelated donors, are available. We here report the clinical co...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-008-0466-z

    authors: Buchholz S,Dammann E,Koenecke Ch,Stadler M,Franzke A,Blasczyk R,Bremer M,Krauter J,Hertenstein B,Ganser A,Eder M

    更新日期:2008-07-01 00:00:00

  • Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.

    abstract::Hypermethylation of CpG islands near gene promoter regions is associated with transcriptional inactivation and represents an important mechanism of gene silencing in carcinogenesis. Such epigenetic phenomena can act alongside DNA mutations and deletions to disrupt tumor-suppressor gene function. The methylation status...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-005-0005-0

    authors: Galm O,Wilop S,Lüders C,Jost E,Gehbauer G,Herman JG,Osieka R

    更新日期:2005-12-01 00:00:00

  • Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.

    abstract::The aim of this phase IV study was to (1) to define efficacy of escalating dose imatinib in chronic myeloid leukemia (CML) patients showing suboptimal response to standard dose imatinib and (2) to find markers that predict the response to escalating doses of imatinib. CML patients in chronic phase (CP) who failed to a...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-010-0910-8

    authors: Koh Y,Kim I,Yoon SS,Kim BK,Kim DY,Lee JH,Lee KH,Park E,Kim HJ,Sohn SK,Joo YD,Kim SJ,Chung J,Shin HJ,Kim SH,Kim CS,Song HS,Kim MK,Hyun MS,Ahn JS,Jung CW,Park S,Korean Society of Hematology CML working party.

    更新日期:2010-07-01 00:00:00

  • Genetic polymorphisms of HbE/beta thalassemia related to clinical presentation: implications for clinical diversity.

    abstract::HbE/Beta thalassemia (HbE/β-thalassemia) is one of the common genetic disorders in South East Asia. It is heterogeneous in its clinical presentation and molecular defects. There are genetic modifiers which have been reported to influence the disease severity of this disorder. The aim of this study was to determine the...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-020-03927-5

    authors: Azman NF,Abdullah WZ,Hanafi S,Diana R,Bahar R,Johan MF,Zilfalil BA,Hassan R

    更新日期:2020-04-01 00:00:00

  • Central nervous system involvement in adults with haemophagocytic lymphohistiocytosis: a single-center study.

    abstract::Hemophagocytic lymphohistiocytosis (HLH) is a rare multisystem disorder characterized by proliferation and diffuse infiltration multiple organs with histiocytes, including the central nervous system (CNS). Neurological manifestations of HLH have been recognized in different studies with children, but they remain relat...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-017-3035-5

    authors: Cai G,Wang Y,Liu X,Han Y,Wang Z

    更新日期:2017-08-01 00:00:00

  • Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.

    abstract::Recent developments in the field of targeted therapy have led to the discovery of a new drug, plerixafor, that is a specific inhibitor of the CXCR4 receptor. Plerixafor acts in concert with granulocyte colony-stimulating factor (G-CSF) to increase the number of stem cells circulating in the peripheral blood (PB). Ther...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-010-1098-7

    authors: Basak GW,Knopinska-Posluszny W,Matuszak M,Kisiel E,Hawrylecka D,Szmigielska-Kaplon A,Urbaniak-Kujda D,Dybko J,Zielinska P,Dabrowska-Iwanicka A,Werkun J,Rzepecki P,Wroblewska W,Wiktor-Jedrzejczak W

    更新日期:2011-05-01 00:00:00

  • Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia.

    abstract::Many studies have confirmed that overexpressed WT1 exists in leukemic cells, especially in AML. However, the immunophenotypic features of this sort of leukemic cells remain to be unclarified. We retrospectively analyzed the immunophenotype of 283 newly diagnosed AML patients with intermediated and poor cytogenetic ris...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-019-03808-6

    authors: Wang XR,Chang Y,Yuan XY,Wang YZ,Qin YZ,Ruan GR,Lai YY,Liu YR

    更新日期:2020-02-01 00:00:00

  • Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

    abstract::Bortezomib synergizes with melphalan in preclinical and early clinical studies. Updated data from our phase 1/2 study assessing the safety and efficacy of bortezomib plus melphalan in relapsed/refractory multiple myeloma (MM) are presented. Bortezomib (0.7, 1.0, or 1.3 mg/m(2)) on days 1, 4, 8, and 11 and oral melphal...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-008-0501-0

    authors: Berenson JR,Yang HH,Vescio RA,Nassir Y,Mapes R,Lee SP,Wilson J,Yellin O,Morrison B,Hilger J,Swift R

    更新日期:2008-08-01 00:00:00

  • Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.

    abstract::Bleomycin-induced pneumonitis (BIP) has been well described in Hodgkin's lymphoma (HL) patients. The impact of BIP on patients uniformly treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) is not clear; previous studies have included patients treated with both ABVD and hybrid regimens. We reviewed ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-010-1032-z

    authors: Ngeow J,Tan IB,Kanesvaran R,Tan HC,Tao M,Quek R,Lim ST

    更新日期:2011-01-01 00:00:00

  • Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.

    abstract::This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated aggressive lymphoma. One hundred and fifteen patients with untreated aggressive lymphoma were stratified by center, age, and international prognostic index and randomized to one of two treatment ar...

    journal_title:Annals of hematology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00277-009-0811-x

    authors: Fridrik MA,Hausmaninger H,Lang A,Drach J,Krieger O,Geissler D,Michlmayr G,Ulsperger E,Chott A,Oberaigner W,Greil R

    更新日期:2010-03-01 00:00:00